Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
REVENUES        
Neurometric services $ 79,800 $ 31,900 $ 133,100 $ 54,100
Telepsychiatry services 380,100 448,800
Total revenues 459,900 31,900 581,900 54,100
OPERATING EXPENSES        
Cost of revenue 298,300 3,800 383,200 7,600
Research 73,400 29,300 154,900 60,900
Product development 342,200 292,800 611,400 588,100
Sales and marketing 638,000 191,800 1,305,200 297,500
General and administrative 1,740,900 934,200 3,515,800 1,955,900
Total operating expenses 3,092,800 1,451,900 5,970,500 2,910,000
OPERATING LOSS (2,632,900) (1,420,000) (5,388,600) (2,855,900)
OTHER INCOME (EXPENSE):        
Interest expense, net (24,800) (1,400) (38,500) (3,900)
Total other income (expense) (24,800) (1,400) (38,500) (3,900)
LOSS BEFORE PROVISION FOR INCOME TAXES (2,657,700) (1,421,400) (5,427,100) (2,859,800)
Income taxes 1,900 30,600 1,900 32,400
NET LOSS $ (2,659,600) $ (1,452,000) $ (5,429,000) $ (2,892,200)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share): $ (0.61) $ (0.61) $ (1.25) $ (1.29)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic and Diluted (in shares) 4,362,564 2,372,394 4,347,745 2,236,728